Pediatric metabolic liver diseases: Evolving role of liver transplantation
World Journal of Transplantation · 18.06.2021 · 11 (6) · 161-179
DOI: 10.5500/wjt.v11.i6.161 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Transplantation, erschienen am 18.06.2021. Verfasst von Jagadeesh Menon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Metabolic liver diseases (MLD) are the second most common indication for liver transplantation (LT) in children. This is based on the fact that the majority of enzymes involved in various metabolic pathways are present within the liver and LT can cure or at least control the disease manifestation. LT is also performed in metabolic disorders for end-stage liver disease, its sequelae including hepatocellular cancer. It is also performed for preventing metabolic crisis', arresting progression of neurological dysfunction with a potential to reverse symptoms in some cases and for preventing damage to end organs like kidneys as in the case of primary hyperoxalosis and methyl malonic acidemia. Pathological findings in explant liver with patients with metabolic disease include unremarkable liver to steatosis, cholestasis, inflammation, variable amount of fibrosis, and cirrhosis. The outcome of LT in metabolic disorders is excellent except for patients with mitochondrial disorders where significant extrahepatic involvement leads to poor outcomes and hence considered a contraindication for LT. A major advantage of LT is that in the post-operative period most patients can discontinue the special formula which they were having prior to the transplant and this increases their well-being and improves growth parameters. Auxiliary partial orthotopic LT has been described for patients with noncirrhotic MLD where a segmental graft is implanted in an orthotopic position after partial resection of the native liver. The retained native liver can be the potential target for future gene therapy when it becomes a clinical reality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India.
- Department of Pathology, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India. mukul.vij.path@gmail.com.
- Department of Transfusion Medicine, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India.
Zitieren
APA
Menon, J., Vij, M., Sachan, D., Rammohan, A., Shanmugam, N., Kaliamoorthy, I., & Rela, M. (2021). Pediatric metabolic liver diseases: Evolving role of liver transplantation. World Journal of Transplantation, 11(6), 161-179. https://doi.org/10.5500/wjt.v11.i6.161
Vancouver
Menon J, Vij M, Sachan D, Rammohan A, Shanmugam N, Kaliamoorthy I, et al. Pediatric metabolic liver diseases: Evolving role of liver transplantation. World Journal of Transplantation. 2021;11(6):161-179. doi:10.5500/wjt.v11.i6.161
BibTeX
@article{Menon2021,
author = {Menon, Jagadeesh and Vij, Mukul and Sachan, Deepti and Rammohan, Ashwin and Shanmugam, Naresh and Kaliamoorthy, Ilankumaran and Rela, Mohamed},
title = {Pediatric metabolic liver diseases: Evolving role of liver transplantation},
journal = {World Journal of Transplantation},
year = {2021},
volume = {11},
number = {6},
pages = {161--179},
doi = {10.5500/wjt.v11.i6.161}
}
EUVIMED